BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28134924)

  • 21. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.
    McLellan JS
    Curr Opin Virol; 2015 Apr; 11():70-5. PubMed ID: 25819327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
    Jones HG; Ritschel T; Pascual G; Brakenhoff JPJ; Keogh E; Furmanova-Hollenstein P; Lanckacker E; Wadia JS; Gilman MSA; Williamson RA; Roymans D; van 't Wout AB; Langedijk JP; McLellan JS
    PLoS Pathog; 2018 Mar; 14(3):e1006935. PubMed ID: 29509814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.
    Blais N; Gagné M; Hamuro Y; Rheault P; Boyer M; Steff AM; Baudoux G; Dewar V; Demers J; Ruelle JL; Martin D
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28404847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein.
    Huang J; Chopra P; Liu L; Nagy T; Murray J; Tripp RA; Boons GJ; Mousa JJ
    J Virol; 2021 Aug; 95(18):e0059321. PubMed ID: 34160259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein.
    Huang J; Miller RJ; Mousa JJ
    Front Immunol; 2022; 13():941865. PubMed ID: 36003370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein.
    Gilman MS; Moin SM; Mas V; Chen M; Patel NK; Kramer K; Zhu Q; Kabeche SC; Kumar A; Palomo C; Beaumont T; Baxa U; Ulbrandt ND; Melero JA; Graham BS; McLellan JS
    PLoS Pathog; 2015 Jul; 11(7):e1005035. PubMed ID: 26161532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
    Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
    McCool RS; Musayev M; Bush SM; Derrien-Colemyn A; Acreman CM; Wrapp D; Ruckwardt TJ; Graham BS; Mascola JR; McLellan JS
    J Virol; 2023 Oct; 97(10):e0092923. PubMed ID: 37737588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B.
    Cairns TM; Fontana J; Huang ZY; Whitbeck JC; Atanasiu D; Rao S; Shelly SS; Lou H; Ponce de Leon M; Steven AC; Eisenberg RJ; Cohen GH
    J Virol; 2014 Mar; 88(5):2677-89. PubMed ID: 24352457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.
    McLellan JS; Yang Y; Graham BS; Kwong PD
    J Virol; 2011 Aug; 85(15):7788-96. PubMed ID: 21613394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
    Chen Z; Zhang L; Tang A; Callahan C; Pristatsky P; Swoyer R; Cejas P; Nahas D; Galli J; Cosmi S; DiStefano D; Hoang VM; Bett A; Casimiro D; Vora KA
    PLoS One; 2016; 11(6):e0156798. PubMed ID: 27258388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development and properties of neutralizing monoclonal antibodies for fusion protein of respiratory syncytial virus.].
    Kushch AA; Klimova RR; Fedorova NE; Masalova OV; Niconova AA; Lesnova EI; Momotyuk ED; Demidova NA; Samartseva TG; Zverev VV
    Vopr Virusol; 2019; 64(2):90-96. PubMed ID: 31412175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.
    McLellan JS; Chen M; Chang JS; Yang Y; Kim A; Graham BS; Kwong PD
    J Virol; 2010 Dec; 84(23):12236-44. PubMed ID: 20881049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.
    Harshbarger W; Abeyrathne PD; Tian S; Huang Y; Chandramouli S; Bottomley MJ; Malito E
    MAbs; 2021; 13(1):1955812. PubMed ID: 34420474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.
    McLellan JS; Chen M; Leung S; Graepel KW; Du X; Yang Y; Zhou T; Baxa U; Yasuda E; Beaumont T; Kumar A; Modjarrad K; Zheng Z; Zhao M; Xia N; Kwong PD; Graham BS
    Science; 2013 May; 340(6136):1113-7. PubMed ID: 23618766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient opening of trimeric prefusion RSV F proteins.
    Gilman MSA; Furmanova-Hollenstein P; Pascual G; B van 't Wout A; Langedijk JPM; McLellan JS
    Nat Commun; 2019 May; 10(1):2105. PubMed ID: 31068578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.